Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O'Halloran PJ, Ward E, Cocchiglia S, Hartmaier R, Castro CA, Zhu L, Tseng GC, Lucas PC, Puhalla SL, Brufsky AM, Hamilton RL, Mathew A, Leone JP, Basudan A, Hudson L, Dwyer R, Das S, O'Connor DP, Buckley PG, Farrell M, Hill ADK, Oesterreich S, Lee AV, Young LS. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.J Natl Cancer Inst. 2018 Jun 28.

Ward E, Varešlija D, Charmsaz S, Fagan A, Browne AL, Cosgrove N, Cocchiglia S, Purcell SP, Hudson L, Das S, O'Connor D, O'Halloran PJ, Sims AH, Hill AD, Young LS. Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer Clin Cancer Res. 2018 Aug 1;24(15):3692-3703. doi: 10.1158/1078-0432.CCR-17-2615. Epub 2018 Mar 22.

Browne AL, Charmsaz S, Varešlija D, Fagan A, Cosgrove N, Cocchiglia S, Purcell S, Ward E, Bane F, Hudson L, Hill AD, Carroll JS, Redmond AM, Young LS. Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. Oncogene. 2018 Jan 25. PMID:29367763. doi: 10.1038/s41388-017-0042.

Charmsaz S, Hughes É Bane F, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy B, O'Dwyer R, Kerin M, Hill A. Young L. (2017) S100β as a Serum Marker in Endocrine Resistant Breast Cancer. BMC Medicine 15(1):79.

Varešlija D., Cocchiglia S., Byrne C., Young L. (2017) Patient-Derived Xenografts of Breast Cancer. In: Martin F., Stein T., Howlin J. (eds) Mammary Gland Development. Methods in Molecular Biology, vol 1501. Humana Press, New York, NY

Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV. (2016) Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncology. 3(5):666-671.

Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT. (2016) RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of the National Cancer Institute. 108(8).

Varešlija D, McBryan J, Fagan A, Redmond AM, Hao Y, Sims AH, Turnbull A, Dixon JM, Ó Gaora P, Hudson L, Purcell S, Hill AD, Young LS. (2016) Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors. Clinical Cancer Research 22(11):2765-77

McBryan J, Fagan A, McCartan D, Bane FT, Varešlija D, Cocchiglia S, Byrne C, Bolger J, McIlroy M, Hudson L, Tibbitts P, Gaora PÓ, Hill AD, Young LS. (2015) Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clinical Cancer Research, 21(23), 5371-5379.

This article was featured in Highlights of the Clinical Cancer Research Issue in December 2015.

Collins DC, Cocchiglia S, Tibbitts P, Solon G, Bane FT, McBryan J, Treumann A, Eustace A, Hennessy B, Hill AD, Young LS. (2015) Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer. Oncogene, 34(4), 525.

Pathiraja TN,[…], Young LS, Schiff R, Li W, and Oesterreich S. (2014) Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer. Science Translational Medicine, 6(229).

Redmond AM, Byrne C, Bane FT, Brown GD, Tibbitts P, O'Brien K, Hill AD, Carroll JS, Young LS. (2014) Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells. Oncogene, 34(29), 3871.

Qin L, Wu YL, Toneff MJ, Li D, Liao L, Gao X, Bane FT, Tien JC, Xu Y, Feng Z, Yang Z, Xu Y, Theissen SM, Li Y, Young L, Xu J. (2014) NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis. Cancer research, 74(13), 3477-3488.

Walsh CA, Bolger JC, Byrne C, Cocchiglia S, Hao Y, Fagan A, Qin L, Cahalin A, McCartan D, McIlroy M, O’Gaora P, Xu J, Hill AD, Young LS. (2014) Global gene repression by SRC-1 promotes oncogenesis. Cancer research, 74(9), 2533-2544.

O’Hara J, Vareslija D, McBryan J, Bane F, Tibbitts P, Byrne C, Conroy RM, Hao Y, O’Gaora P, Hill ADK, McIlroy M, Young LS. (2012) AIB1: ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells. Clinical Cancer Research, 18(12), 3305-3315.

McBryan J, Theissen, SM, Byrne, C, Hughes E, Cocchiglia, S., Sande S, O’Hara J, Tibbitts P, Hill ADK, Young LS. (2012) Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1. Cancer Research, 72(2), 548-559.

McCartan D, Bolger JC, Fagan A, Byrne C, Hao Y, Qin L, McIlroy M, Xu J, Hill AD, O’Gaora P, Young LS. (2012) Global Characterization of the SRC-1 Transcriptome Identifies ADAM22 as an ER-Independent Mediator of Endocrine-Resistant Breast Cancer. Cancer research, 72(1), 220-229.